SCHEMBL2814070

SCHEMBL2814070

CC(C)(C)OC(=O)N1CCCC(NCCCO)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.49
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
EPHX1 P07099 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
HDAC4 P56524 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HPGD P15428 1/20 0.43
PARP1 P09874 1/20 0.43
GLS O94925 1/20 0.42
BRD4 O60885 1/20 0.41
NR1H2 P55055 1/20 0.41
TRPV3 Q8NET8 1/20 0.41
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
ANO1 Q5XXA6 2/20 0.41
PBK Q96KB5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30999407 0.92 EPHX1 (0.49) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL1990841 0.92 USP30 (0.51) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL2892910 0.90 USP30 (0.49) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL28779683 0.89 USP30 (0.48) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL28779682 0.89 USP30 (0.48) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL6128815 0.88 USP30 (0.52) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL2729153 0.88 USP30 (0.52) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL28779716 0.88 USP30 (0.52) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL20986886 0.87 USP30 (0.51) USP30MEN1ALDH1A1MAPTKMT2A
SCHEMBL20986582 0.87 USP30 (0.51) USP30MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411387-B1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY VETDC INC (US) 2015-08-19 EP disclosed
US-9108980-B2 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy VETDC, INC. (US) 2015-08-18 US disclosed
US-20150038486-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY ELANCO US INC. 2015-02-05 US disclosed
US-8772287-B2 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy VETDC, INC. (US) 2014-07-08 US disclosed
US-20130289016-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY ELANCO US INC. 2013-10-31 US disclosed
US-8461158-B2 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy PATHWAY THERAPEUTICS INC. (US) 2013-06-11 US disclosed
US-20100249099-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY PATHWAY THERAPEUTICS LIMITED (NZ) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249099-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY PAICS, CCNI, TYMS USP30 4484/4885MEN1 2556/4885ALDH1A1 318/4885
US-20150038486-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY PAICS, CCNI, TYMS USP30 4484/4885MEN1 2556/4885ALDH1A1 318/4885
US-20130289016-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY PAICS, CCNI, TYMS USP30 4484/4885MEN1 2556/4885ALDH1A1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.